91063-60-4Relevant academic research and scientific papers
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Vuorinen, Aini,Wilkinson, Isabel V.L.,Chatzopoulou, Maria,Edwards, Ben,Squire, Sarah E.,Fairclough, Rebecca J.,Bazan, Noelia Araujo,Milner, Josh A.,Conole, Daniel,Donald, James R.,Shah, Nandini,Willis, Nicky J.,Martínez, R. Fernando,Wilson, Francis X.,Wynne, Graham M.,Davies, Stephen G.,Davies, Kay E.,Russell, Angela J.
supporting information, (2021/05/03)
Duchenne muscular dystrophy is a fatal disease with no cure, caused by lack of the cytoskeletal protein dystrophin. Upregulation of utrophin, a dystrophin paralogue, offers a potential therapy independent of mutation type. The failure of first-in-class utrophin modulator ezutromid/SMT C1100 in Phase II clinical trials necessitates development of compounds with better efficacy, physicochemical and ADME properties and/or complementary mechanisms. We have discovered and performed a preliminary optimisation of a novel class of utrophin modulators using an improved phenotypic screen, where reporter expression is derived from the full genomic context of the utrophin promoter. We further demonstrate through target deconvolution studies, including expression analysis and chemical proteomics, that this compound series operates via a novel mechanism of action, distinct from that of ezutromid.
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead
Mologni, Luca,Dalla Via, Martina,Chilin, Adriana,Palumbo, Manlio,Marzaro, Giovanni
, p. 1390 - 1398 (2017/09/01)
Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.
Facile synthesis of 2,4-diamino-6-alkyl- or 6-aryl-pyrimidine derivatives
Wang, Xihong,Sathunuru, Ramadas,Melendez, Victor,Kozar, Michael P.,Lin, Ai J.
experimental part, p. 1056 - 1061 (2010/10/21)
(Chemical Equation Presented) Facile methods were developed to prepare a series of 6-phenyl and 6-alkyl-2,4-diaminopyrimidine derivatives. The pyrimidine ring of the final products was constructed by treatment of a 1,3-dicarbonyl derivative with an amidin
Metalation of diazines X: First halogen migration during metalation of pyrimidines unusual halogen-lithium exchange with LTMP new synthesis of Leshmaniacides
Ple,Turck,Couture,Queguiner
, p. 10299 - 10308 (2007/10/02)
An halogen migration of iodine during the metalation of pyrimidines has been highlighted and a mechanism is proposed. An unusual halogen-lithium exchange with LTMP has been observed. A new synthetic route to Leshmaniacides using metalation and cross coupl
